CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
2.660
+0.100 (3.91%)
At close: Nov 22, 2024, 4:00 PM
2.700
+0.039 (1.48%)
After-hours: Nov 22, 2024, 5:07 PM EST
CureVac Revenue
CureVac had revenue of 14.44M EUR in the quarter ending June 30, 2024, with 90.47% growth. This brings the company's revenue in the last twelve months to 65.86M, up 75.12% year-over-year. In the year 2023, CureVac had annual revenue of 53.76M, down -20.26%.
Revenue (ttm)
65.86M EUR
Revenue Growth
+75.12%
P/S Ratio
8.45
Revenue / Employee
56,194 EUR
Employees
1,172
Market Cap
596.68M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Talkspace | 181.29M |
Axogen | 180.86M |
Standard BioTools | 155.90M |
Stoke Therapeutics | 16.74M |
Immunome | 10.13M |
Mereo BioPharma Group | 1.00M |
CVAC News
- 11 days ago - CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - Accesswire
- 16 days ago - CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - Accesswire
- 19 days ago - CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - Accesswire
- 19 days ago - CureVac to Present at the 12th International mRNA Health Conference - Accesswire
- 26 days ago - CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Accesswire
- 6 weeks ago - Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents - Reuters
- 2 months ago - CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress - Accesswire